Company / Working Capital
NovaBay Pharmaceuticals, Inc. Working Capital History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
-$908.0K
FY2024
5-year range
-$908.0K / $11.4M
FY2020-FY2024
Trend
-131.6%
vs FY2023
Sector context
#211 of 215
Health Care
What the data says
Among 215 Health Care companies, NovaBay Pharmaceuticals, Inc. is in the bottom 2% for working capital. Working Capital has declined for 4 consecutive years, from $11M in FY2020 to -$908,000 in FY2024.
Based on SEC 10-K filings.
-$908,000 in FY2024.
Declined from $7M to -$908,000 over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 215This company -$908.0K Sector average $957.8M
▼
-100.1% below sector average
Key checks
Key Insights
- NovaBay Pharmaceuticals, Inc.'s working capital has declined for 4 consecutive years.
- In FY2024, working capital decreased 131.6% year-over-year.
- Ranks #211 out of 215 companies in the Health Care sector.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$908.0K | -131.6% |
| FY2023 | $2.9M | -59.3% |
| FY2022 | $7.1M | -27.3% |
| FY2021 | $9.7M | -14.7% |
| FY2020 | $11.4M | +208.9% |
| FY2019 | $3.7M | -22.4% |
| FY2018 | $4.8M | +18.6% |
| FY2017 | $4.0M | -60.4% |
| FY2016 | $10.1M | +9673.6% |
| FY2015 | -$106.0K | -102.9% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026